Immunovant reported earnings of -$ 0.47 per IMVT share on Nov 9, 2026, falling short of analysts' expectations by
| Report Date | Nov 9, 2026 |
|---|---|
| Forecasted EPS | -$ 0.74 |
| Earnings Per Share (Surprise) | -$ 0.47 (+$ 0.267) |
| Last Year's EPS | -$ 0.65 |
| EPS YoY Change |
Out of the last 34 earnings reporting periods, Immunovant beat analysts’ expectations 10 times and fell short of expectations 17 time(s). Immunovant reported earnings per share of -$ 0.47 in the last report surpassing an estimated EPS of -$ 0.74 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.74 | -$ 0.47 | -$ 0.73 | |
| Aug 6, 2026 | -$ 0.63 | -$ 0.75 | -$ 0.60 | |
| May 20, 2026 | -$ 0.59 | -$ 0.73 | -$ 0.64 | |
| Feb 6, 2026 | -$ 0.72 | -$ 0.61 | -$ 0.76 | |
| Nov 10, 2025 | -$ 0.72 | -$ 0.73 | -$ 0.74 | |
| Aug 11, 2025 | -$ 0.69 | -$ 0.60 | -$ 0.60 | |
| May 29, 2025 | -$ 0.71 | -$ 0.64 | -$ 0.52 | |
| Feb 6, 2025 | -$ 0.73 | -$ 0.76 | -$ 0.36 | |
| Nov 7, 2024 | -$ 0.61 | -$ 0.74 | -$ 0.45 | |
| Aug 6, 2024 | -$ 0.53 | -$ 0.60 | -$ 0.57 | |
| May 29, 2024 | -$ 0.43 | -$ 0.52 | -$ 0.46 | |
| Feb 12, 2024 | -$ 0.43 | -$ 0.36 | -$ 0.49 | |
| Nov 9, 2023 | -$ 0.47 | -$ 0.45 | -$ 0.41 | |
| Aug 10, 2023 | -$ 0.45 | -$ 0.57 | -$ 0.35 | |
| May 22, 2023 | -$ 0.43 | -$ 0.46 | -$ 0.41 | |
| Feb 3, 2023 | -$ 0.39 | -$ 0.49 | -$ 0.36 | |
| Nov 4, 2022 | -$ 0.39 | -$ 0.41 | -$ 0.35 | |
| Aug 5, 2022 | -$ 0.40 | -$ 0.35 | -$ 0.31 | |
| Jun 8, 2022 | -$ 0.38 | -$ 0.41 | -$ 0.29 | |
| Feb 4, 2022 | -$ 0.33 | -$ 0.36 | -$ 0.32 |
Immunovant’s stock was trading at $ 30.53 on Nov 8, 2026 a day before the last earnings report was released.Following the release of the earnings report, IMVT’s price increased to $ 35.71 on Nov 10, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.47 | $ 30.53 | $ 35.71 | |
| Aug 6, 2026 | -$ 0.75 | $ 39.28 | $ 39.95 | |
| May 20, 2026 | -$ 0.73 | $ 26.29 | $ 34.13 | |
| Feb 6, 2026 | -$ 0.61 | $ 24.06 | $ 27.49 | |
| Nov 10, 2025 | -$ 0.73 | $ 23.35 | $ 22.89 | |
| Aug 11, 2025 | -$ 0.60 | $ 15.46 | $ 15.21 | |
| May 29, 2025 | -$ 0.64 | $ 14.10 | $ 14.85 | |
| Feb 6, 2025 | -$ 0.76 | $ 22.51 | $ 20.41 | |
| Nov 7, 2024 | -$ 0.74 | $ 31.42 | $ 30.65 | |
| Aug 6, 2024 | -$ 0.60 | $ 26.71 | $ 26.98 | |
| May 29, 2024 | -$ 0.52 | $ 28.42 | $ 26.41 | |
| Feb 12, 2024 | -$ 0.36 | $ 35.50 | $ 36.92 | |
| Nov 9, 2023 | -$ 0.45 | $ 33.39 | $ 32.63 | |
| Aug 10, 2023 | -$ 0.57 | $ 20.92 | $ 22.47 | |
| May 22, 2023 | -$ 0.46 | $ 21.21 | $ 22.24 | |
| Feb 3, 2023 | -$ 0.49 | $ 18.29 | $ 18.41 | |
| Nov 4, 2022 | -$ 0.41 | $ 11.92 | $ 12.67 | |
| Aug 5, 2022 | -$ 0.35 | $ 4.38 | $ 5.23 | |
| Jun 8, 2022 | -$ 0.41 | $ 4.27 | $ 3.73 | |
| Feb 4, 2022 | -$ 0.36 | $ 6.02 | $ 5.86 |
Immunovant released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Immunovant beat analysts’ expectations during the last earnings period by
